Dr. Chiarle received his M.D. degree from the University of Torino, Italy, and is currently Professor of Pathology at Boston Children’s Hospital/Harvard Medical School and at the University of Torino Medical School. He also is appointed as Director of the Hematopathology unit at the European Research Institute (IEO) in Milan, Italy. He has won several national and international awards, including awards from the Italian National Academy of Science, three European Research Council (ERC) grants including the 2025 ERC Advanced Grant, an AICR-UK award, several NIH grants and grants from the LUNGevity foundation, V Foundation, the Ellison Foundation, the Bridge Project and others. 

One major research interest has been to study the mechanisms and pathways of tumor formation activated by the ALK oncogene, as well as the development of innovative therapies for AK-positive cancers, such as an ALK-specific cancer immunotherapy. Recently, the group has developed an ALK vaccine that instructs the immune system to recognize and eliminate ALK-positive lymphoma and lung cancer cells as well as CAR-T and TCR-T cells to target ALK+ tumors including lung cancer, lymphoma and neuroblastoma. He is the founder of ALKEMIST Bio, a company created in 2023 to develop ALK-directed immunotherapies.